

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trudemurk Office' Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/004,993	12	2/05/2001	Jesper Vind	10070.200-US	10070.200-US 9234	
25908	7590	10/01/2003			es.	
NOVOZYMES NORTH AMERICA, INC.				EXAMINER -		
500 FIFTH AVENUE SUITE 1600				HORLICK, KENNETH R		
NEW YORK	, NY 101	10		ART UNIT	PAPER NUMBER	
				1637	13	
,			1	DATE MAILED: 10/01/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)					
Office Action Comments	10/004,993	VIND, JESPER					
Office Action Summary	Examin r	Art Unit					
	Kenneth R Horlick	1637					
The MAILING DATE of this communication app Period for Reply	ears on the c ver sheet with th c	orresp ndence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONED	ely filed will be considered timely. he mailing date of this communication. (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on							
	s action is non-final.						
3) Since this application is in condition for alloward closed in accordance with the practice under E	nce except for formal matters, pro	osecution as to the merits is					
Disp sition of Claims	ex parte Quayle, 1955 C.D. 11, 4	03 O.G. 213.					
4) Claim(s) 1-18 is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	n from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-18</u> is/are rejected.	Claim(s) <u>1-18</u> is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or Application Papers	election requirement.						
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accept	ted or b)⊡ objected to by the Exan	niner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	ved by the Examiner.					
If approved, corrected drawings are required in rep							
12) The oath or declaration is objected to by the Exa	aminer.						
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f).					
a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents							
2. Certified copies of the priority documents		•					
 3. Copies of the certified copies of the priori application from the International Burn * See the attached detailed Office action for a list of 	eau (PCT Rule 17.2(a)).	_					
14) Acknowledgment is made of a claim for domestic			ı).				
a) ☐ The translation of the foreign language prov 15)☐ Acknowledgment is made of a claim for domestic	visional application has been rece	eived.	,				
Attachment(s)	, , , , , , , , , , , , , , , , , , , ,						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 8-1	5) Notice of Informal D	(PTO-413) Paper No(s) atent Application (PTO-152)					

Application/Control Number: 10/004,993

Art Unit: 1637

1. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

Page 2

- 2. Claims 4 and 10-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- A) Claims 4, 10, 12, and 13 are confusing because of the language "preferably", as the scope cannot be determined. Applicant may wish to consider the use of further dependent claims to cover the desired limitations.
- B) Claims 10 and 11 are confusing because "the thermostable mismatch repair protein(s)" lacks proper antecedent basis in claim 1. It would appear that dependency from claim 9 is intended. Correction is required.
- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 17 and 18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed,

Application/Control Number: 10/004,993

Art Unit: 1637

had possession of the claimed invention. These claims are product-by-process claims drawn to any and every possible plurality of recombined polynucleotides, or recombined polynucleotides, generated by the method of claim 1. Clearly, at the time of the invention the inventor was not in possession of such subject matter. In Technology Center 1600, such claims are referred to as "reach-through" claims, as protection is sought for any and every possible product which might possibly be made or identified by a given method. Surely there is no written descriptive basis for claims of this scope; further, there is no basis for a search of the prior art, as the claimed polynucleotides are described merely by the method of making devoid of any physical or even functional properties.

Page 3

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-18 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 99/29902.

These claims are drawn to a method comprising forming heteroduplexes between homologous double-stranded template polynucleotides, and allowing a mismatch repair protein(s) to repair mismatches in the heteroduplexes, wherein recombined new duplexes are formed.

WO 99/29902 discloses such a method (see pages 2-5 and 9-20). The teachings include use of non-methylated templates, use of PCR to generate templates, enzymes such as lipases, use of methylation-deficient cells, and repeated cycles of recombination.

5. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Resnick et al. (US 5,334,522).

Resnick et al. disclose the claimed method; see columns 2-7 and claim 2.

- 6. Arnold et al. (US 6,537,746), a U.S. patent corresponding to WO 99/29902, is made of record as a reference of interest. WO 02/46396, related to the instant application, is also made of record as a reference of interest.
- 7. No claims are free of the prior art.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth R Horlick whose telephone number is 703-308-3905. The examiner can normally be reached on Monday-Thursday 6:30AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 10/004,993

Art Unit: 1637

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Kenneth R Horlick Primary Examiner Art Unit 1637 Page 5

09/23/03